Floatz logo

LIDOCAINE

Diabetic Polyneuropathy

Seoul National University HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Diabetic Polyneuropathy cohort.

Asset / SponsorPhaseRating
Duloxetine
University of Rochester
Phase 4BB
Pregabalin
Syeda Khatoon e Jannat Welfare Foundation
Phase 4BB
(±)-TRAMADOL
Turku University Hospital
Phase 4BB
Capsaicin
Thammasat University
Phase 2/3B
Adezunap
Apurano Pharmaceuticals GmbH
Phase 3B

View all 20 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →